A Dutch case-control study of 148,000 adults showed that among those with type 1 diabetes, average LDL-cholesterol and blood pressure levels diverged from those of the general background population.
A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally reported. But FOURIER trialists stand by their conclusions.
Age- and sex-related differences in the relationship between levels of a bone-derived hormone, osteocalcin, and cardiometabolic risk factors are apparent in study of patients with type 2 diabetes.